Search
Nicoboxil
go.drugbank.com/drugs/DB12911ApprovedWithdrawnSuch combination topical analgesics are only available for purchase and use (for humans) in some parts of Europe and Asia, like Germany and Australia [F11, F16]. … and capability to be used as an alternative musculoskeletal pain therapy option with less systemic side effects when compared to the oral non-steroidal anti-inflammatory drugs and opioids that may be
Carbidopa
go.drugbank.com/drugs/DB00190ApprovedInvestigationaltherapy developed by Mayne Pharma in 1992. … An individual formulation containing solely carbidopa was generated to treat nausea in patients where the combination therapy [levodopa]/carbidopa is not efficient reducing nausea.
Mixtures: LEV/CAR/EN AL100/25/200, LEV/CAR/EN AL200/50/200Bictegravir
go.drugbank.com/drugs/DB11799ApprovedInvestigationalIt has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.[L43677] … Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection.
Categories: Antivirals used in combination for the treatment of HIV infectionsEstriol
go.drugbank.com/drugs/DB04573ApprovedInvestigationalVet approvedIt has also been approved and marketed throughout Europe and Asia for approximately 40 years for the treatment of post-menopausal hot flashes. … It is however available in the United States by prescription filled only by compounding pharmacies.
International brands: Synapause EEmtricitabine
go.drugbank.com/drugs/DB00879ApprovedInvestigationalin high risk adolescents and adults. … [L9019] Emtricitabine was granted FDA approval on 2 July 2003.[L9019]
Mixtures: EMTRICITABINA E TENOFOVIR DISOPROXIL EG, EMTRICITABINA E TENOFOVIR DISOPROXIL EGCategories: Antivirals used in combination for the treatment of HIV infectionsMigalastat
go.drugbank.com/drugs/DB05018ApprovedInvestigational[L47036,L47057] As of August 2018, migalastat under Amicus Therapeutics' brand name Galafold is currently approved in Australia, Canada, European Union, Israel, Japan, South Korea, Switzerland, and … This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys, the nerves, the heart, and other
Edoxudine
go.drugbank.com/drugs/DB13421ApprovedWithdrawnIt was later recognized to be effective in vivo in a preclinical model of keratitis caused by herpes virus. … The obtained product is an antiviral ointment.[L2407] The activity of edoxudine against herpes simplex virus was first recognized in 1967.
Aripiprazole
go.drugbank.com/drugs/DB01238ApprovedInvestigational[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002.[L6136] … [L45859] It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania.
Products: ARIPIPRAZOLO EGFormestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnIt is not US FDA approved, and the intramuscular injection form of formestane (Lentaron) which was approved in Europe has been withdrawn. … Currently, formestane (categorized as an anti-estrogenic agent) is prohibited from use in sports in accordance to the regulations of the World Anti-Doping Agency.
Diroximel fumarate
go.drugbank.com/drugs/DB14783ApprovedInvestigational[A176474] It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. … Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019[L9626] and by the EMA in November 2021.[L39225]